ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Mylan Seeks To Buy Rival Perrigo

by Michael McCoy
April 13, 2015 | APPEARED IN VOLUME 93, ISSUE 15

The generic drug maker Mylan has proposed to acquire its rival Perrigo in a cash and stock deal valued at close to $29 billion. The combined firm would be one of the world’s leading suppliers of generic and over-the-counter drugs, with annual sales of more than $15 billion. Mylan and Perrigo are both former U.S.-based firms that incorporated in Europe through inversion acquisitions: Mylan bought Abbott’s European generics business last year, and Perrigo acquired Ireland’s Elan in 2013. Perrigo says it has received the proposal and that its board will discuss it.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment